Opioid-Induced Bowel Dysfunction

Journal of Pain and Symptom Management

Volumn 35, Issue 1, 2008, Pages 103-113

  Thomas, Jay ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

alvimopan; constipation; methylnaltrexone; Opioid

Indexed keywords

17 METHYLNALTREXONE; ALVIMOPAN; BISACODYL; CISAPRIDE; CODEINE; COLCHICINE; DOCUSATE SODIUM; LUBIPROSTONE; METHADONE; METOCLOPRAMIDE; MISOPROSTOL; MORPHINE; NALOXONE; NEOSTIGMINE; OPIATE; PLACEBO; SENNA EXTRACT; TEGASEROD;

ABDOMINAL CRAMP; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DRUG ABSORPTION; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG WITHDRAWAL; ENTEROPATHY; FLATULENCE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL TRACT FUNCTION; HEART DISEASE; HUMAN; IRRITABLE COLON; MELANOSIS; MONOTHERAPY; NAUSEA; NONHUMAN; OGILVIE SYNDROME; PRURITUS; REVIEW; UNSPECIFIED SIDE EFFECT; VOMITING;

ANALGESICS, OPIOID; ANIMALS; GASTROINTESTINAL DISEASES; GASTROINTESTINAL TRACT; HUMANS; NARCOTIC ANTAGONISTS;

EID: 37349073398     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jpainsymman.2007.01.017     Document Type: Review

References (51)

1. Pappagallo M. Incidence, prevalence, and management of opioid bowel dysfunction. Am J Surg 182 (2001) 11S-18S
2. Sykes N.P. The relationship between opioid use and laxative use in terminally ill cancer patients. Palliat Med 12 (1998) 375-382
3. In: Johnson L.R. (Ed). Gastrointestinal physiology. 6th ed. (2001), Mosby Elsevier, Philadelphia, PA
4. In: Feldman M., Friedman L.S., and Sleisinger M.H. (Eds). Sleisenger & Fordtran's gastrointestinal and liver disease. 7th ed. (2002), Saunders, Philadelphia, PA
5. Shetzline M.A., and Liddle R.A. Gastrointestinal hormones and neurotransmitters. In: Feldman M., Friedman L.S., and Sleisenger M.H. (Eds). Sleisenger & Fordtran's gastrointestinal and liver disease. 7th ed. (2002), Saunders, Philadelphia, PA 3-20
6. Gershon M.D. Serotonin receptors and transporters-roles in normal and abnormal gastrointestinal motility. Aliment Pharmacol Ther 20 Suppl 7 (2004) 3-14
7. Cook I.J., and Brookes S.J. Motility of the large intestine. In: Feldman M., Friedman L.S., and Sleisenger M.H. (Eds). Sleisenger & Fordtran's gastrointestinal and liver disease. 7th ed. (2002), Saunders, Philadelphia, PA 1679-1692
8. Garvey M., Noyes Jr. R., and Yates W. Frequency of constipation in major depression: relationship to other clinical variables. Psychosomatics 31 (1990) 204-206
9. Sternini C., Patierno S., Selmer I.S., and Kirchgessner A. The opioid system in the gastrointestinal tract. Neurogastroenterol Motil 16 Suppl 2 (2004) 3-16
10. Kaufman P.N., Krevsky B., Malmud L.S., et al. Role of opiate receptors in the regulation of colonic transit. Gastroenterology 94 (1988) 1351-1356
11. Galligan J.J., and Burks T.F. Centrally mediated inhibition of small intestinal transit and motility by morphine in the rat. J Pharmacol Exp Ther 226 (1983) 356-361
12. Porreca F., Heyman J.S., Mosberg H.I., et al. Role of mu and delta receptors in the supraspinal and spinal analgesic effects of [D-Pen2, D-Pen5]enkephalin in the mouse. J Pharmacol Exp Ther 241 (1987) 393-400
13. Jiang Q., Sheldon R.J., and Porreca F. Opioid modulation of basal intestinal fluid transport in the mouse: actions at central, but not intestinal, sites. J Pharmacol Exp Ther 253 (1990) 784-790
14. Basilisco G., Camboni G., Bozzani A., et al. Oral naloxone antagonizes loperamide-induced delay of orocecal transit. Dig Dis Sci 32 (1987) 829-832
15. Van Nueten J.M., Van Ree J.M., and Vanhoutte P.M. Inhibition by met-enkephalin of peristaltic activity in the guinea pig ileum, and its reversal by naloxone. Eur J Pharmacol 41 (1977) 341-342
16. Wood J.D., and Galligan J.J. Function of opioids in the enteric nervous system. Neurogastroenterol Motil 16 Suppl 2 (2004) 17-28
17. Crain S.M., and Shen K.F. Opioids can evoke direct receptor-mediated excitatory effects on sensory neurons. Trends Pharmacol Sci 11 (1990) 77-81
18. North R.A., and Henderson G. Action of morphine on guinea-pig myenteric plexus and mouse vas deferens studied by intracellular recording. Life Sci 17 (1975) 63-66
19. Morita K., and North R.A. Opiates and enkephalin reduce the excitability of neuronal processes. Neuroscience 6 (1981) 1943-1951
20. De Luca A., and Coupar I.M. Insights into opioid action in the intestinal tract. Pharmacol Ther 69 (1996) 103-115
21. Fenn G.C., Wilkinson P.D., Lee C.E., and Akbar F.A. A general practice study of the efficacy of Regulan in functional constipation. Br J Clin Pract 40 (1986) 192-197
22. Ashraf W., Park F., Lof J., and Quigley E.M. Effects of psyllium therapy on stool characteristics, colon transit and anorectal function in chronic idiopathic constipation. Aliment Pharmacol Ther 9 (1995) 639-647
23. Sykes N.P. A volunteer model for the comparison of laxatives in opioid-related constipation. J Pain Symptom Manage 11 (1996) 363-369
24. Ponec R.J., Saunders M.D., and Kimmey M.B. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med 341 (1999) 137-141
25. Soffer E.E., Metcalf A., and Launspach J. Misoprostol is effective treatment for patients with severe chronic constipation. Dig Dis Sci 39 (1994) 929-933
26. Roarty T.P., Weber F., Soykan I., and McCallum R.W. Misoprostol in the treatment of chronic refractory constipation: results of a long-term open label trial. Aliment Pharmacol Ther 11 (1997) 1059-1066
27. Verne G.N., Davis R.H., Robinson M.E., et al. Treatment of chronic constipation with colchicine: randomized, double-blind, placebo-controlled, crossover trial. Am J Gastroenterol 98 (2003) 1112-1116
28. Camilleri M., Bharucha A.E., Ueno R., et al. Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers. Am J Physiol Gastrointest Liver Physiol 290 (2006) G942-G947
29. Lyden-Sokolowski A., Nilsson A., and Sjoberg P. Two-year carcinogenicity study with sennosides in the rat: emphasis on gastro-intestinal alterations. Pharmacology 47 Suppl 1 (1993) 209-215
30. Mitchell J.M., Mengs U., McPherson S., et al. An oral carcinogenicity and toxicity study of senna (Tinnevelly senna fruits) in the rat. Arch Toxicol 80 (2006) 34-44
31. Sykes N.P. Oral naloxone in opioid-associated constipation. Lancet 337 (1991) 1475
32. Sykes N.P. An investigation of the ability of oral naloxone to correct opioid-related constipation in patients with advanced cancer. Palliat Med 10 (1996) 135-144
33. Liu M., and Wittbrodt E. Low-dose oral naloxone reverses opioid-induced constipation and analgesia. J Pain Symptom Manage 23 (2002) 48-53
34. Wilker A., Fraser H., and Isbell H. N-allylnormomorphine: effects of single doses and precipitation of acute abstinence syndromes during addiction to morphine, methadone, or heroin in man. J Pharmacol Exp Ther 109 (1953) 8-20
35. Gonenne J., Camilleri M., Ferber I., et al. Effect of alvimopan and codeine on gastrointestinal transit: a randomized controlled study. Clin Gastroenterol Hepatol 3 (2005) 784-791
36. Paulson D.M., Kennedy D.T., Donovick R.A., et al. Alvimopan: an oral, peripherally acting, mu-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction-a 21-day treatment-randomized clinical trial. J Pain 6 (2005) 184-192
37. Schmidt W.K. Alvimopan* (ADL 8-2698) is a novel peripheral opioid antagonist. Am J Surg 182 (2001) 27S-38S
38. Liu S.S., Hodgson P.S., Carpenter R.L., and Fricke Jr. J.R. ADL 8-2698, a trans-3,4-dimethyl-4-(3-hydroxyphenyl) piperidine, prevents gastrointestinal effects of intravenous morphine without affecting analgesia. Clin Pharmacol Ther 69 (2001) 66-71
39. Yuan C.S., Doshan H., Charney M.R., et al. Tolerability, gut effects, and pharmacokinetics of methylnaltrexone following repeated intravenous administration in humans. J Clin Pharmacol 45 (2005) 538-546
40. Yuan C.S., Wei G., Foss J.F., et al. Effects of subcutaneous methylnaltrexone on morphine-induced peripherally mediated side effects: a double-blind randomized placebo-controlled trial. J Pharmacol Exp Ther 300 (2002) 118-123
41. Yuan C.S., and Foss J.F. Oral methylnaltrexone for opioid-induced constipation. JAMA 284 (2000) 1383-1384
42. Yuan C.S., Foss J.F., O'Connor M., et al. Effects of enteric-coated methylnaltrexone in preventing opioid-induced delay in oral-cecal transit time. Clin Pharmacol Ther 67 (2000) 398-404
43. Yuan C.S., Foss J.F., O'Connor M., et al. Methylnaltrexone for reversal of constipation due to chronic methadone use: a randomized controlled trial. JAMA 283 (2000) 367-372
44. Murphy D.B., Sutton J.A., Prescott L.F., and Murphy M.B. Opioid-induced delay in gastric emptying: a peripheral mechanism in humans. Anesthesiology 87 (1997) 765-770
45. Yuan C.S., Foss J.F., Osinski J., et al. The safety and efficacy of oral methylnaltrexone in preventing morphine-induced delay in oral-cecal transit time. Clin Pharmacol Ther 61 (1997) 467-475
46. Yuan C.S., Foss J.F., O'Connor M., et al. Methylnaltrexone prevents morphine-induced delay in oral-cecal transit time without affecting analgesia: a double-blind randomized placebo-controlled trial. Clin Pharmacol Ther 59 (1996) 469-475
47. Zimmerman D.M., Gidda J.S., Cantrell B.E., et al. Discovery of a potent, peripherally selective trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine opioid antagonist for the treatment of gastrointestinal motility disorders. J Med Chem 37 (1994) 2262-2265
48. Russell J., Bass P., Goldberg L.I., et al. Antagonism of gut, but not central effects of morphine with quaternary narcotic antagonists. Eur J Pharmacol 78 (1982) 255-261
49. Amin H.M., Sopchak A.M., Foss J.F., et al. Efficacy of methylnaltrexone versus naloxone for reversal of morphine-induced depression of hypoxic ventilatory response. Anesth Analg 78 (1994) 701-705
50. Yuan C.S., Foss J.F., O'Connor M., et al. Efficacy of orally administered methylnaltrexone in decreasing subjective effects after intravenous morphine. Drug Alcohol Depend 52 (1998) 161-165
51. Yuan C.S., Foss J.F., O'Connor M., et al. Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study. Pain 83 (1999) 631-635